Search PubMed⌕ Search

Biomedical subjects

S Klimek

Publications and source records attributed to S Klimek.

At least 19 recordsLinked to original sources
PubMed2001

The Hamilton SPE Evaluation Tool (HSET): is it any good?

Presents the Hamilton Supervised Pastoral Evaluation Tool (HSET). HSET is a self-report that evaluates student learning in a basic SPE unit utilizing six areas: supervisory relationship, personal growth, professional growth, theological reflection, learning context, and overall growth. Reviews statistics involving seven regional units consisting of 18 SPE units with 101 students. Utilizes methodological, investigator, and data triangulation by drawing on qualitative study and CAPPE accreditation review. Discusses strengths and weaknesses of HSET and makes recommendations for further use.

Accreditation↗
PubMed1987

Sensitivity differences in reproductive/endocrine organs to chronically administered LHRH agonists in female rats.

The acute and chronic effects of two LHRH agonists on reproductive endocrine target organs were examined in female rats. Animals were injected twice daily with [(ImBzl)-D-His6,Pro9-NEt]LHRH (histrelin) or [D-Trp6,Pro9-NEt]LHRH for 1, 3, 5, 7, 11 or 28 days at 1, 10, 100 or 1000 micrograms/kg/day beginning in the luteal phase. The responses observed with the two agonists were similar. An initial stimulatory phase was observed on the first day of treatment with substantial increases in serum LH and progesterone levels. A significant diminution of hormone response was seen by day 3. Only 1000 micrograms/kg abolished the pituitary LH response at later treatment periods. Estrous cyclicity, ovarian and uterine weight, and progesterone and estradiol levels were inhibited in a time and dose dependent manner. The results demonstrate target organ sensitivity differences. In contrast to the relatively high doses needed to inhibit the pituitary response and decrease ovarian weight, doses as low as 1 microgram/kg were sufficient to decrease uterine weight. If these findings extrapolate to humans, it may be that conditions in which the desired therapeutic action is suppression of uterine tissue, may be treated with lower doses of LHRH agonists than conditions requiring complete gonadal suppression.

Adrenal Glands↗
PubMed1987

A comparison of the potencies and activities of progestogens used in contraceptives.

The potencies and activities of six progestational agents, norethindrone, levonorgestrel, desogestrel, medroxyprogesterone acetate (MPA), progesterone (P) and norgestimate have been evaluated using standard laboratory bioassays. The endocrine activities measured are those most closely related to the clinically important actions of contraceptives. Relative potencies varied with parameter measured, route of administration and species showing clearly that each progestogen is a distinct pharmacological entity. The order of potency using oral administration for either ovulation inhibition or endometrial stimulation in rabbits was desogestrel greater than levonorgestrel greater than MPA greater than norgestimate greater than norethindrone. Levonorgestrel was more androgenic than desogestrel, and P, norethindrone, norgestimate and MPA were essentially devoid of androgen activity. This profile demonstrates clear differences in the potencies and activities of these progestogens and in their selectivity for target organs.

Androgens↗
PubMed1984

Potency and activity variation of LHRH analogs in different models and species.

The LHRH agonist [D-His(Bzl)6, Pro9-NHEt]LHRH was estimated to be 3.4, 4.4 and 9.2 times more potent than LHRH as a stimulator of ovulation in Nembutal-anesthetized, androgen-sterilized and diestrus rats, respectively; and 57 times more potent than LHRH as a stimulator of uterine growth in immature mice. Higher doses of agonist were required to induce ovulation in diestrus hamsters and mice than were needed in diestrus rats. Rats and hamsters also exhibited different sensitivities to an antagonist of LHRH. The LHRH antagonist [N-Ac delta 3-Pro1, D-pF-Phe2,D-Trp3,6]LHRH was active but higher doses were required to inhibit ovulation in hamsters than were needed in rats. In addition, treatment at 1500 hr on the day of proestrus in rats, in contrast to treatment at 1000 hr in hamsters, caused the greatest inhibition of ovulation. It is clear from these data, that the estimated in vivo potencies of analogs of LHRH are greatly influenced by species and animal model, as well as route of administration and biopharmaceutic factors previously reported.

Animals↗